Otlertuzumab

Otlertuzumab (TRU‐016) is a humanized monoclonal antibody that targets CD37[1] designed for the treatment of cancer.[2]

Otlertuzumab
Monoclonal antibody
Type?
SourceHumanized (from mouse)
TargetCD37
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
Chemical and physical data
FormulaC4660H7136N1246O1452S30
Molar mass104809.42 g·mol−1

This drug was developed by Emergent BioSolutions and has been in clinical trials for lymphoma and Chronic Lymphocytic Leukemia (CLL)[3]

References

  1. Payandeh Z, Noori E, Khalesi B, Mard-Soltani M, Abdolalizadeh J, Khalili S (December 2018). "Anti-CD37 targeted immunotherapy of B-Cell malignancies". Biotechnology Letters. 40 (11–12): 1459–1466. doi:10.1007/s10529-018-2612-6. PMID 30293139. S2CID 52925605.
  2. "Otlertuzumab" (PDF). Statement On A Nonproprietary Name Adopted By The USAN Council. American Medical Association.
  3. "Otlertuzumab". ClinicalTrails.gov. U.S. National Library of Medicine.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.